[go: up one dir, main page]

MX336214B - Derivados de pirrolotriazinona como inhibidores de pi3k. - Google Patents

Derivados de pirrolotriazinona como inhibidores de pi3k.

Info

Publication number
MX336214B
MX336214B MX2013011781A MX2013011781A MX336214B MX 336214 B MX336214 B MX 336214B MX 2013011781 A MX2013011781 A MX 2013011781A MX 2013011781 A MX2013011781 A MX 2013011781A MX 336214 B MX336214 B MX 336214B
Authority
MX
Mexico
Prior art keywords
pi3k inhibitors
pyrrolotriazinone derivatives
pyrrolotriazinone
derivatives
inhibitors
Prior art date
Application number
MX2013011781A
Other languages
English (en)
Other versions
MX2013011781A (es
Inventor
Ferrer Jordi Gracia
Anchuela Francisco Javier Bernal
Riera Marta Carrascal
Javaloyes Juan Francisco Caturla
Víctor Giulio Matassa
Belart Emma Terricabras
Moll Joan Taltavull
Sola Montserrat Erra
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2013011781A publication Critical patent/MX2013011781A/es
Publication of MX336214B publication Critical patent/MX336214B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)

Abstract

(Ver Formula) Se describen nuevos derivados de pirrolotriazinona que tienen la estructura química de fórmula (I); así como un procedimiento para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia como inhibidores de Fosfoinositido 3-quinasas (PI3Ks).
MX2013011781A 2011-04-29 2012-04-26 Derivados de pirrolotriazinona como inhibidores de pi3k. MX336214B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382124A EP2518070A1 (en) 2011-04-29 2011-04-29 Pyrrolotriazinone derivatives as PI3K inhibitors
US201161502550P 2011-06-29 2011-06-29
PCT/EP2012/057671 WO2012146666A1 (en) 2011-04-29 2012-04-26 Pyrrolotriazinone derivatives as pi3k inhibitors

Publications (2)

Publication Number Publication Date
MX2013011781A MX2013011781A (es) 2013-11-01
MX336214B true MX336214B (es) 2016-01-12

Family

ID=44484054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011781A MX336214B (es) 2011-04-29 2012-04-26 Derivados de pirrolotriazinona como inhibidores de pi3k.

Country Status (37)

Country Link
US (1) US9340547B2 (es)
EP (2) EP2518070A1 (es)
JP (1) JP5903160B2 (es)
KR (1) KR20140021622A (es)
CN (1) CN103649089B (es)
AR (1) AR086144A1 (es)
AU (1) AU2012247491B2 (es)
BR (1) BR112013023876A2 (es)
CA (1) CA2826197A1 (es)
CL (1) CL2013003073A1 (es)
CO (1) CO6801747A2 (es)
CR (1) CR20130543A (es)
CY (1) CY1116871T1 (es)
DK (1) DK2702061T3 (es)
EA (1) EA024350B1 (es)
ES (1) ES2545853T3 (es)
GT (1) GT201300266A (es)
HK (1) HK1195552A1 (es)
HR (1) HRP20151153T1 (es)
HU (1) HUE026041T2 (es)
IL (1) IL227764A (es)
ME (1) ME02210B (es)
MX (1) MX336214B (es)
MY (1) MY171553A (es)
PE (1) PE20141193A1 (es)
PH (1) PH12013502059A1 (es)
PL (1) PL2702061T3 (es)
PT (1) PT2702061E (es)
RS (1) RS54270B1 (es)
SG (1) SG194084A1 (es)
SI (1) SI2702061T1 (es)
SM (1) SMT201500270B (es)
TW (2) TWI535720B (es)
UA (1) UA111197C2 (es)
UY (1) UY34051A (es)
WO (1) WO2012146666A1 (es)
ZA (1) ZA201305612B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
MD20150048A2 (ro) * 2012-10-16 2015-10-31 Almirall S.A. Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
CN104870017B (zh) * 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
MX2015006192A (es) * 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
WO2014082230A1 (zh) * 2012-11-28 2014-06-05 上海希迈医药科技有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
PT2935246T (pt) * 2012-12-21 2018-10-10 Gilead Calistoga Llc Inibidores de fosfatidilinositol 3-quinase de quinazolinona ou isoquinolinona
BR112015014585A2 (pt) 2012-12-21 2017-07-11 Gilead Calistoga Llc composto, composição farmacêutica, e, método de tratamento de um ser humano
TW201446767A (zh) * 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
MX347988B (es) * 2013-06-14 2017-05-19 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-cinasa.
BR112016003019A2 (pt) * 2013-08-13 2017-09-12 Univ Illinois composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
CN111494386A (zh) * 2014-04-08 2020-08-07 因赛特公司 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
BR112016024538A2 (pt) * 2014-05-27 2017-08-15 Almirall Sa sais de adição de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-di-hidro¬pirrolo[1,2-f][1,2,4]triazina-5-carbonitrila
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2015274626C1 (en) 2014-06-13 2018-08-09 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
ES2750357T3 (es) * 2014-06-13 2020-03-25 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
JP6291601B2 (ja) 2014-07-04 2018-03-14 ルピン・リミテッド Ｐｉ３ｋ阻害剤としてのキノリジノン誘導体
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017008867A2 (pt) 2014-11-01 2017-12-26 Chongqing Fochon Pharmaceutical Co Ltd inibidores de proteína quinases
JP6668253B2 (ja) 2014-11-26 2020-03-18 武田薬品工業株式会社 二環性化合物
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
WO2017160930A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
EP3672597A4 (en) * 2017-08-21 2021-09-22 Navigen, Inc. ARF6 INHIBITORS AND RELATED PROCEDURES
CN111212839A (zh) 2017-09-15 2020-05-29 艾杜罗生物科技公司 吡唑并嘧啶酮化合物及其用途
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
MX2020013192A (es) 2018-06-04 2021-08-16 Arcutis Inc Metodo y formulacion para mejorar el tiempo de retraso de penetracion en la piel de roflumilast.
CN112384514A (zh) * 2018-07-06 2021-02-19 利奥制药有限公司 作为janus激酶抑制剂的新的氨基-咪唑并嘧啶衍生物及其药物用途
JP2022541954A (ja) * 2019-07-17 2022-09-28 小野薬品工業株式会社 Ｋｄｍ５阻害活性を有する化合物およびその医薬用途
CN111346095B (zh) * 2020-03-14 2021-06-08 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 用于治疗神经外科术后头痛的药物制剂
EP4149944A4 (en) * 2020-05-16 2024-07-03 Fochon Biosciences, Ltd. COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
US5200416A (en) * 1980-05-12 1993-04-06 Usv Pharmaceutical Corporation Cyclic amides
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
WO1992004928A2 (en) 1990-09-26 1992-04-02 Pharbita B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
DK0674533T3 (da) 1992-12-18 1999-09-27 Schering Corp Inhalator for medikamenter i pulverform
DK0820323T3 (da) 1995-04-14 2003-11-24 Smithkline Beecham Corp Inhalator til afmålte doser af salmeterol
CN1181896C (zh) 1995-06-21 2004-12-29 索福泰克两合公司 带整体计量装置的药筒和药粉吸入器
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005047280A1 (en) 2003-11-10 2005-05-26 Merck Sharp & Dohme Limited Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ATE481996T1 (de) 2004-07-16 2010-10-15 Almirall Sa Inhalator für die abgabe von pharmzeutischen pulver, und ein pulverkassette zur verwendung mit diesem inhalator
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
NZ565749A (en) * 2005-08-26 2010-12-24 Serono Lab Pyrazine derivatives and use as PI3K inhibitors
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
CN102439012A (zh) * 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
US8754089B2 (en) 2009-06-25 2014-06-17 Amgen Inc. Heterocyclic compounds and their uses
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods

Also Published As

Publication number Publication date
SI2702061T1 (sl) 2016-01-29
UA111197C2 (uk) 2016-04-11
DK2702061T3 (en) 2015-11-09
MX2013011781A (es) 2013-11-01
PH12013502059A1 (en) 2019-10-11
CN103649089A (zh) 2014-03-19
TW201247674A (en) 2012-12-01
CA2826197A1 (en) 2012-11-01
WO2012146666A1 (en) 2012-11-01
EA201301209A1 (ru) 2014-04-30
EP2702061B9 (en) 2016-02-24
PL2702061T3 (pl) 2016-01-29
PT2702061E (pt) 2015-10-26
HUE026041T2 (en) 2016-05-30
CL2013003073A1 (es) 2014-02-21
SG194084A1 (en) 2013-11-29
TW201242967A (en) 2012-11-01
US9340547B2 (en) 2016-05-17
CR20130543A (es) 2014-03-17
AU2012247491B2 (en) 2016-08-18
CN103649089B (zh) 2016-06-29
PE20141193A1 (es) 2014-09-03
EA024350B1 (ru) 2016-09-30
CY1116871T1 (el) 2017-04-05
EP2518070A1 (en) 2012-10-31
TWI535720B (zh) 2016-06-01
EP2702061B1 (en) 2015-07-29
UY34051A (es) 2012-11-30
HK1195552A1 (en) 2014-11-14
CO6801747A2 (es) 2013-11-29
GT201300266A (es) 2015-04-06
US20150099752A9 (en) 2015-04-09
RS54270B1 (en) 2016-02-29
HRP20151153T1 (hr) 2015-12-04
JP5903160B2 (ja) 2016-04-13
JP2014515027A (ja) 2014-06-26
AR086144A1 (es) 2013-11-20
IL227764A0 (en) 2013-09-30
IL227764A (en) 2016-07-31
US20140163033A1 (en) 2014-06-12
KR20140021622A (ko) 2014-02-20
BR112013023876A2 (pt) 2016-12-13
EP2702061A1 (en) 2014-03-05
SMT201500270B (it) 2016-01-08
NZ614082A (en) 2015-05-29
AU2012247491A1 (en) 2013-08-15
ES2545853T3 (es) 2015-09-16
ZA201305612B (en) 2014-05-28
MY171553A (en) 2019-10-18
ME02210B (me) 2016-02-20

Similar Documents

Publication Publication Date Title
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
PH12015500813B1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX336381B (es) Boronatos como inhibidores de arginasa.
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
MD20140002A2 (ro) Indazoli
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
NZ708870A (en) Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
MY177344A (en) Compounds and their methods of use
MX2013010898A (es) Novedoso derivados de la pirimidina.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
UY35087A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP15015088A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors